Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03104842 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Evaluation iNduction, Consolidation and Maintenance Treatment With Isatuximab , Carfilzomib, LEnalidomide and Dexamethasone

StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Re-verified, no change to tracked fieldsv11
  2. Primary completion date: Feb 2025 to May 2026
    • Publications: details revised at 1 of 5 entries
    v10
  3. Primary completion date: Jul 2023 to Feb 2025
    • Study sites: 18 to 17
    • Study completion date: Jul 2024 to Sep 2026
    • Eligibility criteria revised
    v9
  4. Trial status: Recruiting to Active, Not Recruiting
    • Study sites: 19 to 18
    v8
  5. Eligibility criteria revised
    • Publications: 4 to 5
    v7
Show 5 earlier versionsHide 5 earlier versions
  1. Trial status: Active, Not Recruiting to Recruiting
    • Enrollment target: 153 to 246
    • Site details revised at 19 of 19 sites
    v6
  2. Lead sponsor: University Hospital Tuebingen to Universitätsklinikum Hamburg-Eppendorf
    • Trial status: Recruiting to Active, Not Recruiting
    • Site details revised at 19 of 19 sites
    v5
  3. Study sites: 15 to 19v4
  4. Study sites: 11 to 15v3
  5. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Jul 2017 to Aug 15, 2017
    • Site details revised at 11 of 11 sites
    v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
A Clinical Phase II, multicenter, Open-label study evaluating iNduction, consolidation and maintenance treatment with Isatuximab (SAR650984), Carfilzomib, LEnalidomide and Dexamethasone (I-KRd) in Primary diagnosed high-risk multiple myeloma paTients
Trial Details
NCT Number NCT03104842
Lead Sponsor Universitätsklinikum Hamburg-Eppendorf
Conditions
(from sponsor)		 Multiple Myeloma
Related terms Multiple Myeloma
Enrollment 246 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov